Module

The Use of Antiangiogenic Agents in the Treatment of Breast Cancer

Source: Innovative Approaches to Treating Metastatic Breast Cancer: Patient Selection, Effective Combination Regimens, and Overcoming Resistance

The Use of Antiangiogenic Agents in the Treatment of Breast Cancer

Faculty:

Eric P. Winer, MD

CME CREDIT INFORMATION

Release Date: 03/13/07

Expiration Date: 03/12/08

Physicians: maximum of 0.75 AMA PRA Category 1 Credits™

Status: Please log in to view status

Learning Objectives

Upon completion of this activity, participants should be able to:

Describe recent clinical data on the use of bevacizumab in the treatment of metastatic breast cancer
Summarize the efficacy and safety of novel antiangiogenic agents for treatment of patients with metastatic breast cancer
Discuss recent clinical data regarding small-molecule vascular endothelial growth factor inhibitors in the treatment of breast cancer

Topics covered include:

Introduction
Rationale for Targeting Angiogenesis
Rationale for Bevacizumab Use in Breast Cancer
Eastern Cooperative Oncology Group 2100
Safety Issues Associated With Bevacizumab
Correlative Studies of Bevacizumab Response
Metronomic Chemotherapy
Bevacizumab in Combination With Endocrine Therapy
Adjuvant Trials Using Bevacizumab
Small Molecule Inhibitors of VEGFR
Safety Considerations With Biologic Agents
Conclusion

Disclaimer: The materials published on the Clinical Care Options Web site reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the CME provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.